Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Retained Earnings: 2009-2025

Historic Retained Earnings for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to -$333.5 million.

  • Aytu Biopharma's Retained Earnings fell 4.10% to -$331.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$331.6 million, marking a year-over-year decrease of 4.10%. This contributed to the annual value of -$333.5 million for FY2025, which is 4.24% down from last year.
  • As of FY2025, Aytu Biopharma's Retained Earnings stood at -$333.5 million, which was down 4.24% from -$320.0 million recorded in FY2024.
  • Over the past 5 years, Aytu Biopharma's Retained Earnings peaked at -$178.3 million during FY2021, and registered a low of -$333.5 million during FY2025.
  • Its 3-year average for Retained Earnings is -$319.2 million, with a median of -$320.0 million in 2024.
  • Data for Aytu Biopharma's Retained Earnings shows a maximum YoY slumped of 61.02% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Aytu Biopharma's Retained Earnings stood at -$178.3 million in 2021, then slumped by 61.02% to -$287.1 million in 2022, then dropped by 5.93% to -$304.1 million in 2023, then dropped by 5.21% to -$320.0 million in 2024, then declined by 4.24% to -$333.5 million in 2025.